Despite flat revenue growth, radiation oncology firm Nucletron was able to turn in record earnings in 2009, thanks to an increased focus on product profitability, trimming of its product portfolio, and cost control.
For the year, the Veenendaal, Netherlands-based firm had sales of 113 million euros ($139.9 million U.S.), compared with 112 million euros ($138.7 million U.S.) in 2008. However, Nucletron had record earnings before interest, taxes, depreciation, and amortization (EBITDA) of 20 million euros ($24.8 million U.S.), compared with EBITDA of 17 million euros ($21 million U.S.) in 2008.
Related Reading
Nucletron completes German order, May 24, 2010
Nucletron, ART add AccuBoost customer, May 17, 2010
Nucletron names Tarca to VP post, March 2, 2010
Nucletron, ART install AccuBoost in Europe, February 24, 2010
Nucletron takes more Pilgrim Software, November 25, 2009
Copyright © 2010 AuntMinnie.com
